MorphoSys AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MPSYF research report →
About the company
MorphoSys AG is a biopharmaceutical firm with therapies already on the market, specializing in the discovery, advancement, and commercialization of antibody-based treatments for individuals battling cancer and autoimmune diseases. Among its key offerings is Tafasitamab, an antibody therapy approved for treating specific B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also boasts a robust pipeline, with several promising candidates under development.
- CEO
- Arkadius Pichota
- IPO
- 2010
- Employees
- 524
- HQ
- Planegg, DE
Price Chart
- Market Cap
- $2.76B
- P/E
- -11.99
- P/S
- 10.48
- P/B
- 46.38
- EV/EBITDA
- -30.43
- Div Yield
- 0.00%
- Gross Margin
- 75.51%
- Op Margin
- -105.96%
- Net Margin
- -79.63%
- ROE
- -183.80%
- ROIC
- -14.13%
- Revenue
- $238.28M · -14.37%
- Net Income
- $-189,734,199 · -25.60%
- EPS
- $-5.53 · -25.11%
- Op Income
- $-252,475,802
- FCF YoY
- 21.79%
- 52W High
- $73.27
- 52W Low
- $25.56
- 50D MA
- $73.27
- 200D MA
- $72.22
- Beta
- 0.66
- Avg Volume
- 0
Get TickerSpark's AI analysis on MPSYF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our MPSYF coverage
Recent articles, reports, and earnings notes.
No research on MPSYF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MPSYF report →Similar companies
Peers in the same neighborhood.